Novacea slows down development program for AQ4N

Novacea, which is burning through $17 million to $19 million this year, says it will scale back on the development of AQ4N, shelving a clinical trial in acute lymphoblastic leukemia and delaying a clinical trial in B-cell lymphoma. The news was included in a strategic review of its plans for 2008. An ongoing Phase Ib/IIa clinical trial of AQ4N in patients with glioblastoma multiforme will continue.

"Since we terminated the ASCENT-2 trial in advanced prostate cancer, managing our capital resources, which totaled approximately $110 million in cash and receivables at the end of the third quarter of 2007, is a top priority as we seek to maximize the strategic options available to the company," says Novacea CEO John Walker.

- see Novacea's release
- read the report from Trading Markets

Suggested Articles

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.

In our EuroBiotech roundup this week, a liver disease biotech raises €11 million, Autolus offers stock and Abivax plans midphase trial. 

Merck KGaA spinout iOnctura has raised a €15 million series A round to support an early-phase solid tumor trial of a PI3Kδ inhibitor.